Former FDA Associate Commissioner Says FDA Made Right Move to Authorize Convalescent Plasma

FDA Commissioner Stephen Hahn is under fire after saying on Sunday convalescent plasma treatment for COVID-19 results in a 35 percent improvement rate in survival according to a study. This statistic, cited by President Trump and Health and Human Services Secretary Alex Azar upon authorizing the treatment, is not what the data from the study shows. Hahn then walked back the comments Monday on Twitter, writing that he should have said the treatment shows a relative risk reduction instead of an absolute risk reduction. Former FDA Associate Commissioner Peter Pitts, President for the Center For Medicine in the Public Interest, explains why he believes the FDA authorized the use of convalescent plasma.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.